Top 5 Crowdfunding VC Funds & Investors in Germany (June 2026)

Portfolio highlights

• zolar — With the zolar online configurator, homeowners can customise the components of their PV system to suit their individual requirements and receive personal assistance from one of our solar energy experts at the same time. zolar’s extensive network of local partner companies takes care of the installation on site. The Berlin-based start-up employsaround 200 employees across Germany and pursues the vision of installing a PV system on every roof in the world in order to make private households more independent from the mains grid. The dovetailing of energy generation, electricity storage and mobility allows customers to design electrified and smart households. As a next green energy company, zolar enables its customers to become energy providers for their own four walls, neutralise their carbon footprint and, in turn, make an effective contribution to climate protection.
• TrapLight Games — A hard-hitting mobile game studio from Finland. Traplight is a premium mobile games studio with 10+ years of game development expertise at the highest level. Our ambition is to create world class, chart topping, scalable game services.
• Fast Travel Games — Fast Travel Games is a VR exclusive game developer and publisher, founded by industry leading veterans and behind acclaimed titles such as Apex Construct and Wraith: The Oblivion - Afterlife.

Portfolio highlights

• Homa Games — Leave your mark in the gaming industry. We are building a team of extraordinary individuals working together to build apps that entertain the world. We are experts in every step of the publishing process.
• Closinglock — Closinglock is modernizing the real estate world’s way of transferring information to eliminate wire fraud & protect buyers.
• Carewell — Shop home healthcare supplies like adult diapers, nutrition shakes & first aid. Get 30% off first Autoship. Friendly customer service. Helpful caregiver articles.

Portfolio highlights

• Floy — Floy develops AI-driven software that supports radiologists in detecting complex and hard-to-identify diseases. The collaboration of Floy-AI and radiologists ensures optimal patient outcomes by enabling the early detection and thus early treatment of diseases.One of Floy’s distinguishing features is our innovative incentive structure. We partnerwith radiology offices to jointly offer patients our AI as a “second opinion”. This unique approach motivates radiologists to embrace Floy-AI and encourages widespread adoption.Since its establishment in 2021, Floy secured €8.8 million in funding and rapidly expanded its presence with over 150 radiology locations to date. Floy’s overarching mission is to pioneer proactive medicine by providing exceptional AI-powered diagnostic experiences for health-conscious patients.
• Yapily — Scalable and reliable open banking infrastructure that is built to power the next wave of innovation. Connect to thousands of banks within minutes and access financial data and payment infrastructure via our secure open banking API.
• Impossible Cloud — Experience Impossible Cloud Storage: Secure, scalable, performant. Decentralized architecture, S3 API compatibility, 100% durability. Start free trial now.

Portfolio highlights

• Kvantify — Quantum computing will revolutionize many aspects of computing. We can help your business harness the full potential of Quantum Computing and High-Performance Computing today.
• Ventive Group — Ventive Group is a venture capitalist that provides personalized advice to support innovative startups and SMEs.
• Wave Photonics — Wave Photonics is leading the revolution in rapid PIC design technology. We are enabling rapid, fabrication-tolerant photonic integrated circuit development for any wavelength or platform.

Portfolio highlights

• SIRION BIOTECH — Viral Vector Technology as key enabler for innovative therapeutics. Viral vectors are a tool commonly used by molecular biologists to deliver genetic material into cells. This technique enables research of gene function and innovative therapeutics designed to correct defective genes and cancer. These technologies also assist in the discovery ofnew drug, food and cosmetic compounds. SIRION is a global leader in viral vector technology for gene modification of mammalian cells. Along with custom services, the company stands ready to outlicense its unique technologies. An initial target currently being pursued by one of SIRION's partners is a gene therapeutic for cervical cancer. The company started business in 2007 and since then has been changing the paradigm of viral vector supplies. Specifically, all commonly applied vector types are now available within a matter of weeks - adenovirus, adeno-associated virus (AAV) and lentivirus - and a full range of virus related services is at your fingertips spanning from particle production to virus driven cell modelling, all at highest titers and in quantities required for preclinical, clinical and animal testing.The company is easily accessible with presence in Munich, Tokyo, New Hampshire and Tel Aviv. Commercial arrangements range from fee-for-service over exclusive rights on single clones all the way to milestone & licensing arrangements. The business model proves successful: an annual 70% growth since 2007 and experienced in more than 500 projects for both the academic and industry sector.The company is privately held and has over the years raised funds from 8 investors both private and government. In order to support further growth and to benefit from technology development in this exciting industry, the company welcomes new investors. Please contact Management for further information about the company and its future plans.
• CryoTherapeutics — CryoTherapeutics is focusing on the development, demonstration of clinical benefit, and early-stage commercialization of a proprietary cryotherapy system for use in the treatment of coronary artery disease that causes heart attacks. The safety and efficacy of cryoenergy in the cardiovascular system has been demonstrated and CryoTherapeutics intendsto extend the benefits of cryoenergy to the problem of diseased coronary arteries.
• Chundsell Medicals — Chundsell Medicals AB was founded in 2007 as a spin off from Karolinska Institutet, Solna, in order to commercialize the research results of Chunde Li and his group on prostate cancer genomics. The first product: The Prostatype® Test System can assess prostate cancer aggressiveness in conjunction with currently used clinical parameters. TheProstatype® Test System measures the expression pattern of three selected and specific prostate cancer embryonic stem cell genes in tumor cell tissue specimens. These expression patterns together with a group of a selected number of known clinical parameters will help the health care professional to predict the disease outcome, the overall survival as well as cancer specific survival of patients.